Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Identify a preferred oral fluconazole dose regimen for patients with non-acute
histoplasmosis or blastomycosis, or ulcerocutaneous or deep sporotrichosis.
II. Study the safety and efficacy of fluconazole in these patients.
Phase:
Phase 2
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) University of Alabama at Birmingham